Remove DNA Remove Genome Remove Production
article thumbnail

STAT+: Pacific Biosciences, known for niche DNA sequencing, looks to rival Illumina with new product launch

STAT News

firm best known for its niche approach to DNA sequencing, on Tuesday announced plans to launch a new product that will put the company in direct competition with genomics juggernaut Illumina. The new DNA sequencer, dubbed Onso, reads the genome in small pieces and uses software to stitch that information together.

DNA 98
article thumbnail

Opinion: Where are the guidelines for the production of animals with intentional genomic alterations?

STAT News

Genetic engineering has the potential to transform how we raise animals for meat and other products, making food safer, improving animal health and welfare, and shrinking animal agriculture’s environmental footprint. Pigs that are less likely to induce allergic reactions in humans. Read the rest…

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: With rivals on its heels, Illumina launches a new line of high-end DNA sequencers

STAT News

SAN DIEGO — After a steep drop in its stock price and with mounting competition from rivals, genomics giant Illumina on Thursday launched a new line of high-powered DNA sequencers, ratcheting up the race to read genetic information accurately and cheaply. Continue to STAT+ to read the full story…

DNA 105
article thumbnail

Vertex signs licence deal with CRISPR Therapeutics for diabetes therapies

Pharmaceutical Technology

The gene-editing technology allows for precise, directed changes to genomic DNA. It edits genes by precisely cutting DNA, then allowing natural DNA repair processes to take over. The system comprises the Cas9 enzyme and a guide RNA.

article thumbnail

Moderna partners with Life Edit for mRNA gene editing therapies

Pharmaceutical Technology

The company will also receive tiered royalties on the worldwide net sales of products developed from the collaboration. The company’s nuclease collection includes several Protospacer Adjacent Motifs (PAMs), short sequences that help determine the genome’s DNA segments.

article thumbnail

The future of the gene therapy market: driving innovations in biotherapeutics

Pharmaceutical Technology

Gene therapy uses DNA to manipulate cells and correct defective genes, whereas cell therapy is the infusion or transplantation of cells into a patient. New doors were opened in the 2000s with the development of genome editing, such as CRISPR-Cas9, which introduces molecular tools to change existing DNA.

article thumbnail

Illumina and Sequoia Capital China Partner to Launch Genomics Incubator in China

The Pharma Data

NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Sequoia Capital China , a leading investment firm, today announced a collaboration to catalyze the startup ecosystem in China with the launch of the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.